Selegiline · Rasagiline · Safinamide — blocking monoamine oxidase-B to extend dopamine's reach in Parkinson's disease
Dopamine released into the synaptic cleft does not last forever. Alongside reuptake by the dopamine transporter (DAT), a major clearance route is enzymatic degradation by monoamine oxidase-B (MAO-B), an enzyme anchored to the outer mitochondrial membrane of glial cells and some neurons. In Parkinson's disease, where dopaminergic neurons are already dying and dopamine supply is scarce, this degradation pathway becomes clinically important: every molecule of dopamine broken down is one fewer available to activate postsynaptic receptors.
Monoamine oxidase-B is a flavin-adenine-dinucleotide (FAD)-dependent enzyme that catalyzes oxidative deamination of monoamines. For dopamine, the reaction converts dopamine + O2 + H2O into 3,4-dihydroxyphenylacetaldehyde (DOPAL), ammonia, and hydrogen peroxide. DOPAL is then rapidly converted by aldehyde dehydrogenase into DOPAC, and subsequently methylated by catechol-O-methyltransferase (COMT) into homovanillic acid (HVA) — the main dopamine metabolite measured in cerebrospinal fluid.
Critically, this reaction generates hydrogen peroxide as a byproduct. In dopaminergic neurons already under oxidative stress in Parkinson's disease, MAO-B-mediated dopamine turnover has long been hypothesized to contribute to reactive oxygen species and neuronal vulnerability — part of the original rationale for testing MAO-B inhibitors as potentially neuroprotective, not just symptomatic, agents (a hypothesis that remains only partially supported by clinical trial evidence).
Because MAO-B activity increases with age and is abundant in glial cells surrounding dopaminergic terminals, it represents a substantial "sink" for extracellular and intraneuronal dopamine — making its pharmacological blockade a rational strategy to preserve what little dopamine remains available in the parkinsonian brain.
Roughly 80% of monoamine oxidase activity in the human brain is attributable to the B isoform, with MAO-A (predominantly metabolizing serotonin and norepinephrine) making up the remainder — this isoform split is what allows selective MAO-B inhibitors to spare serotonergic and noradrenergic pathways at standard clinical doses.
MAO-B inhibitors work by occupying and disabling the enzyme's active site so dopamine can no longer be oxidatively deaminated. Selegiline and rasagiline form irreversible, covalent bonds with the flavin cofactor of MAO-B (mechanism-based, "suicide" inhibition), permanently inactivating each enzyme molecule they bind. Safinamide instead binds reversibly, competing with dopamine for access to the active site without permanently disabling the enzyme. Either way, the practical effect is the same: less dopamine degradation, more dopamine available to activate D1/D2 receptors, and — critically for levodopa-treated patients — a longer functional lifespan for each dose of exogenous dopamine.
When an MAO-B inhibitor occupies the enzyme's active site, dopamine molecules that would otherwise be oxidized instead remain intact — free to diffuse in the extracellular space, be recaptured by the dopamine transporter for re-release, or persist long enough to bind additional postsynaptic dopamine receptors. This does not increase total dopamine synthesis; it increases the effective "dwell time" and total exposure of whatever dopamine is already present — whether produced by surviving nigrostriatal neurons or delivered exogenously as levodopa-derived dopamine.
Because irreversible inhibitors permanently inactivate each MAO-B molecule they bind, the clinical effect outlasts the drug's plasma half-life considerably — full enzyme activity does not return until new enzyme is synthesized, typically over roughly two weeks. Safinamide's reversible binding gives a pharmacodynamic profile that tracks more closely with plasma drug levels.
Selectivity matters clinically: at recommended doses, these drugs preferentially inhibit MAO-B over MAO-A, which limits interference with serotonin and norepinephrine metabolism and reduces (without eliminating) the tyramine-related risks historically associated with older, non-selective monoamine oxidase inhibitors.
In patients with early, mild Parkinson's disease who do not yet require levodopa, an MAO-B inhibitor can be started as a first-line standalone treatment. The symptomatic effect is modest compared to levodopa or dopamine agonists, but it is meaningful enough in mild disease to improve motor scores, and it offers the practical advantage of a simple once-daily dosing regimen with a comparatively mild side-effect profile — attractive reasons to consider it early, including as a strategy to delay levodopa initiation.
Early Parkinson's disease still has substantial numbers of surviving nigrostriatal dopaminergic neurons capable of synthesizing and releasing dopamine. By blocking MAO-B-mediated breakdown, an MAO-B inhibitor amplifies the effect of this endogenous dopamine without adding an exogenous dopamine source. Because the amount of "amplifiable" dopamine depends on how much is still being produced, the ceiling of achievable benefit is inherently lower than with levodopa (which directly supplies the dopamine precursor) or dopamine agonists (which directly stimulate receptors).
In practice, clinicians weigh this modest but real benefit against the drug's low burden of side effects, simple dosing, and the appeal of postponing levodopa — historically motivated partly by concerns about levodopa-induced motor complications with long-term use, though modern data suggest the timing of levodopa initiation matters less than once believed. The decision to use MAO-B inhibitor monotherapy is individualized, weighing symptom severity, patient goals, and tolerability.
Because the symptomatic ceiling of MAO-B inhibitor monotherapy is limited by residual endogenous dopamine production, most patients with early PD will eventually need levodopa or a dopamine agonist added as the disease progresses and dopaminergic neuron loss continues.
As Parkinson's disease advances, levodopa's benefit becomes less smooth: each dose produces a defined "on" period followed by a "wearing-off" decline as plasma and brain dopamine levels fall — often before the next scheduled dose. Adding an MAO-B inhibitor to a levodopa regimen slows the breakdown of the dopamine generated from each levodopa dose, effectively stretching out the "on" window and reducing the frequency and severity of end-of-dose wearing-off.
When levodopa is converted to dopamine in surviving nerve terminals (and in non-neuronal cells via peripheral and central aromatic L-amino acid decarboxylase), the resulting dopamine is subject to the same MAO-B-mediated clearance as endogenously produced dopamine. In patients with wearing-off, the brief window of adequate dopamine concentration after each dose is exactly what MAO-B inhibition can extend — by slowing degradation, more of the dopamine generated from a given levodopa dose remains available for longer, flattening the peak-and-trough pattern that produces "off" periods.
This adjunct strategy is one of several pharmacologic approaches to motor fluctuations, alongside COMT inhibitors (which block a different dopamine-metabolizing pathway) and adjustments to levodopa dosing frequency or formulation. In practice, MAO-B inhibitors are frequently combined with these other strategies, since they act on complementary steps in the dopamine metabolism pathway rather than duplicating each other's mechanism.
The magnitude of benefit is dose- and patient-dependent, and illustrative "on"-time extensions reported in this simulator are meant to convey a directional relationship (higher inhibitor exposure → longer extension) rather than to represent precise clinical trial figures for any specific drug or patient.
Selective MAO-B inhibitors are generally well tolerated at standard clinical doses, but they are not risk-free. Understanding their safety profile requires distinguishing them from older, non-selective monoamine oxidase inhibitors, and being alert to specific drug-interaction scenarios — particularly serotonergic co-medications and, for safinamide, additional pharmacology beyond MAO-B inhibition.
Older, non-selective monoamine oxidase inhibitors (inhibiting both MAO-A and MAO-B) carried a well-known risk: dietary tyramine, normally broken down by intestinal and hepatic MAO before reaching systemic circulation, could accumulate and trigger a hypertensive crisis ("cheese reaction") when both MAO isoforms were blocked. Because MAO-A is the isoform primarily responsible for tyramine metabolism, selective MAO-B inhibitors at their recommended doses largely preserve this protective pathway, making dietary tyramine restriction generally unnecessary at standard dosing. However, selectivity for MAO-B is dose-dependent — at higher-than-recommended doses, selectivity is lost and the classic tyramine interaction risk can re-emerge, which is one reason dosing recommendations are followed carefully.
Even with MAO-A largely spared, MAO-B inhibitors still carry a labeled risk of serotonin syndrome when combined with certain serotonergic medications — including some SSRIs, SNRIs, tricyclic antidepressants, meperidine, tramadol, and certain other opioids and antidepressants. This risk relates to the drugs' effect on monoamine handling broadly and is addressed in prescribing information with recommended washout periods and combinations to avoid or use only with caution and close monitoring.
Safinamide has additional pharmacology beyond MAO-B inhibition: it also modulates voltage-gated sodium channels and glutamate release, contributing to its symptomatic and possibly anti-dyskinetic effects, but also introducing considerations distinct from selegiline and rasagiline (such as caution in patients with certain retinal conditions, reflecting nonclinical findings). As with all adjunct Parkinson's therapies, a full medication reconciliation — checking for interacting antidepressants, opioids, and other serotonergic or MAO-active agents — is an essential safety step before and during treatment.
This simulator's "interaction caution" indicator is informational and illustrative only. Real-world prescribing requires a full review of a patient's complete medication list, renal/hepatic function, and comorbidities by a qualified clinician — it is not a substitute for medical advice.